Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Stay current in the industry and delve into the insights of our global teams of expert industry analysts with pharma news blogs from Pharma Intelligence. Covering an array of specialties and topics, these pharma blogs include discussion of some of the most critical subjects affecting the pharmaceuticals industry today.
81 Total results for product and free and sample content found
Strategic Transactions
Last year, a total of 67 biopharma and medtech companies completed initial public offerings (IPOs), raising for $8.55bn combined.
Datamonitor Healthcare, Scrip, Trialtrove, In...
The tumor-agnostic developer’s toolkit
Datamonitor Healthcare, Biomedtracker, Pharma...
As the biopharma industry concludes its annual pilgrimage to San Francisco for the JP Morgan investor conference, much of the talk around town inevitably was about gene therapies.
Topic Cell and gene therapy
Datamonitor Healthcare, Biomedtracker
Commentators at the ISPOR Europe 2019 conference in Copenhagen debated the challenges that exist with valuing and financing potentially curative treatments, including cell and gene therapies, and cancer immunotherapies. With several recent regulatory approvals of high-cost advanced therapy medicinal products (ATMPs), discussion has ensued in earnest on how to determine their clinical value, and whether traditional reimbursement and health technology assessment (HTA) processes are sufficient to assess these innovative treatments.
Citeline
Recent news of the Ohio State ruling on the opioid litigation trial against Johnson & Johnson shed new light on the complex opioid addiction crisis in the US.
Trialtrove
Trialtrove recently released a major enhancement that indexes primary and secondary endpoints evaluated in clinical trials.
Datamonitor Healthcare
The World Health Organization defines mobile health (mHealth) as a “medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless devices”. In the last decade, the health sector has seen a substantial rise in the number of mHealth apps, many of which are designed to assist users in weight reduction and diabetes management. In 2016, there were 79,000 apps available in the Health & Fitness category in the Google and Apple stores. However, the implementation of mHealth in oncology is lagging, and there are comparatively few available apps. There is a need for the development of more mHealth apps in oncology settings considering the increasing disease burden and potential clinical benefit.
Datamonitor Healthcare, Biomedtracker
Given the transformative nature of regenerative medicines, which can yield greatly improved patient responses, meet unmet need, and now exist as viable products on the market, cell and gene therapeutics developers over the past several years have been drawing deal attention, not only through collaborative partnerships, but also as acquisition targets.
Biomedtracker, Datamonitor Healthcare
With arguably the standout data from the 2019 American Society for Clinical Oncology (ASCO) annual meeting, Amgen has become the first company to show that KRAS, beyond its role as an oncogene, is also a viable drug target
Topic BioPharmaceutical Drug review
No Records Found
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
